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The basic functional unit of hepatitus B virus (HBV) enhancer II (ENII) is located within nt 1687–1774, which is defined
as the B fragment in our previous papers. A major trans-acting factor binding site has been identified within the B fragment.
The sequence corresponding to this binding site was named B2. In this paper, several point mutations were introduced
into the B2 subunit by PCR-mediated site-directed mutagenesis. CAT analysis indicated that the TGTTTGTTT motif within
the B2 subunit was critical for the activity of ENII. Mutations of individual nucleotides within this motif could decrease the
activity of ENII. Electrophoresis mobility shift assay revealed that the liver-enriched transcription factors hepatocyte nuclear
factor (HNF) 3a and HNF3b bound to the B2 subunit specifically and the TGTTTGTTT motif was essential for DNA–protein
interaction. Anti-HNF3a and anti-HNF3b antisera could block such binding ability. Moreover, HNF3b could switch on the
activity of ENII in HeLa cells and the activity of ENII could be suppressed by antisense HNF3a and antisense HNF3b
mRNA in HepG2 cells. These results prompted the conclusion that HNF3 was crucial for the liver-specific activity of ENII,
which in turn contributed significantly to the liver specificity of HBV. q 1995 Academic Press, Inc.
INTRODUCTION We have mapped ENII in a 148-bp fragment ranging from
nt 1627 to 1774, which was upstream of Cp and partly
There are four open reading frames (S, C, P, and X)
overlapped it (Wang et al., 1990). Two apparent trans-
within the genome of human heptitis B virus (HBV) (Ga-
acting factor binding regions were identified, according
nem and Varmus, 1987; Tiollais et al., 1985). Accordingly,
to which ENII was divided into two parts, A and B. Thefour promoters (Sp1, Sp2, Cp, and Xp) are responsible
A fragment (nt 1627–1686) contains one binding regionfor the transcription of the viral mRNAs (Seto et al., 1990;
(nt 1648–1671), while the B fragment (nt 1687–1774), theSpandau and Lee, 1988; Twu and Schloemer, 1987). Core
other (nt 1714–1730). Our previous data (Wu et al., 1992)promoter (Cp) transcribes the pregenomic mRNA and
showed that the B fragment, when tested alone in CATprecore mRNA (Schaller and Fischer, 1991). The former
assay, preserved nearly 70% of enhancer activity. There-serves not only as the template from which viral polymer-
fore, the B fragment was considered the basic functionalase and core antigen are translated, but also the tem-
unit of ENII. According to the binding site of trans-actingplate for reverse transcription, which is a unique feature
factor(s) and functional analysis by CAT assay, B itselfof the replication of a DNA virus. Precore mRNA is trans-
could be further divided into three subunits, B1, B2, andlated to generate a viral e antigen whose function re-
B3. The B2 subunit covers the binding site from nt 1714mains unknown. The most intriguing feature with regard
to 1730. However, the properties of the factor(s) inter-to the transcription of these two mRNAs is their restricted
acting with B2 as well as the function of the B2 fragmentdistribution in certain well-differentiated hepatocytes but
in the context of ENII were unclear.not dedifferentiated liver cell types or nonhepatocytes.
In this report, we demonstrated that the B2 subunit wasThe transcription initiated by Cp requires cooperative
crucial for the function of ENII. Mutations of individualregulation between the promoter and the enhancer. Two
nucleotides within TGTTTGTTT (nt 1719–1727) in the B2enhancer elements (ENI and ENII) have been identified
fragment aborted the activity of ENII significantly, indicat-in the viral genome (Shaul et al., 1985; Tognoni et al.,
ing that the trans-acting factor(s) interacting with B21985; Wang et al., 1990; Yee, 1989; Yuh and Ting, 1990).
played an important role in the activity of ENII. Electro-ENII partly overlaps Cp and shows highly restricted liver-
phoresis mobility shift assay revealed that hepatocytespecific activity, implying that ENII may be the major cis
nuclear factor (HNF) 3a and HNF3b could bind specifi-element regulating the liver-specific transcription initi-
cally to the B2 fragment. However, B2 containing muta-ated by Cp.
tions within the TGTTTGTTT motif lost the ability to inter-HBV ENII is located within the X open reading frame.
act with HNF3. Moreover, HNF3b could switch on the
function of ENII when introduced into HeLa cells. Co-1 The first two authors contributed equally to this work.
transfection experiments also showed that antisense2 To whom correspondence and reprint requests should be ad-
dressed. Fax: 0086-21-4338357. HNF3 mRNA could suppress the activity of ENII in HepG2
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To construct the plasmids pSVpCATAB, pSVpCA-
TAB2ml, and pSVpCATAB2m4, AB (nt 1627–1774), the
ENII fragment (Wang et al., 1990), and its mutated forms
were generated by PCR. Then they were inserted into
XbaI and SmaI sites of pBSK(0) (Stratagene) to obtain
the resultant plasmids pAB, pAB2ml, and pAB2m4. The
SV40 early promoter together with the CAT reporter gene
was then cloned into SacI and XbaI sites which were
upstream of ENII in the above plasmids. The other setFIG. 1. Scheme of plasmid construction. The ABCD fragment con-
of plasmids, pB3CCATAB, pB3CCATAB2ml and pB3CCA-tains viral ENII (AB) and core promoter (CD). B3C is the basic core
promoter of HBV. SVp is the SV40 early promoter. (1) pABCDCAT, which TAB2m4, was constructed similarly, only B3C (nt 1737–
contained viral ENII and Cp located upstream of the CAT gene; (2) 1805) (basic core promoter, unpublished data) was used
pBCDCAT, similar to pABCDCAT in structure, only lacking the A frag-
as the promoter to drive the CAT gene expression in-ment of ENII. (3) pSVpCATAB, which used the SV40 early promoter to
stead of the SV40 early promoter (Fig. 1).drive CAT expression. ENII was located downstream of the CAT gene;
To obtain the eukaryotic expression plasmids which(4) pB3CCATAB, which was similar to the set of the pSVpCATAB plas-
mid in structure, only differing in that B3C (viral basic core promoter) transcribe HNF3a and HNF3b in the antisense orienta-
was used instead of SVp. The number of nucleotides represented the tion, pCMVHNF3a and pCMVHNF3b (Lai et al., 1991;
position of each fragment in the HBV genome.
Pani et al., 1992) were cut first with HindIII, made blunt
by filling in with Klenow fragment of DNA polymerase I,
and then digested with XbaI. The isolated HNF3a andcells, which confirmed the functional importance of
HNF3b cDNA fragments were reinserted into SmaI andHNF3. HNF3 is a family of liver-enriched transcription
XbaI sites of pCMV-poly, respectively, to get the finalfactors including HNF3a, HNF3b, and HNF3g (Lai et al.,
constructs pAntiHNF3a and pAntiHNF3b. pAntiHNF3g1991, 1993), which regulated the expression of several
was generated by inserting the EcoRI fragment of HNF3gliver-specific genes (Lai and Darnell, 1991). Our results
cDNA cut from pTZ18U-HNF3g into the EcoRI site ofsuggested that HNF3 was essential for the activity of
pCMV-poly in the antisense orientation.ENII, which may help explain the liver-specific regulatory
function of ENII.
Cell lines and transfection
Cell lines used in the experiments were HepG2 andMATERIALS AND METHODS
HeLa. All cells were propagated in Dulbecco’s modified
Plasmid construction Eagle’s medium with 10% fetal bovine serum at 5% CO2
and 377.
To construct the plasmids containing mutations within
DNAs were transfected into HepG2 or HeLa cells by
the TGTTTGTTT (nt 1719–1727) motif of the B2 fragment,
the phosphate calcium precipitation method (Sambrook
two pairs of primers were synthesized. The first pair,
et al., 1989). Cells were harvested 48 hr after transfection
ENII–B2ml, bears only one point mutation which
and protein extracts were prepared. The transfection effi-
changed TGTTTGTTT to TCTTTGTTT (5*-CATACTT-
ciency was normalized by the activity of the internal con-
CAAAGACTCTTTG-3*, 5*-CTTAAACAAAGAGTCTTTG-3*).
trol. CAT assay was performed according to the method
The other pair, ENII–B2m4, has four point mutations
of Gorman et al. (1982).
(5*-CATACTTCAAAGACTGGATCCTTAAG-3*, 5*-CCAGT-
In transfection assay of wild-type and mutant ENII plas-
CCTTAAGGATCCAGTCTTTG-3*). These mutations were
mids, 5.0 mg pCH110 (Pharmacia) (Sambrook et al., 1989)
introduced into the ABCD fragment (nt 1627–1878) of the
was cotransfected as internal control. In cotransfection
viral genome, which covers Cp and the entire ENII (Wang
experiments of antisense-HNF3 or HNF3 expression
et al., 1990). Wild-type ABCD and its mutated forms
plasmids, 1.0 mg pCMV/SEAP (Berger et al., 1988) served
(AB2mlCD, AB2m4CD) were generated by PCR site-di-
as internal control, which directs the expression of se-
rected mutagenesis using standard procedure. After di-
creted placental alkaline phosphatase (SEAP) under the
gestion by XbaI and HindIII, the three fragments were
CMV immediate early promoter. The total amount of DNA
inserted into XbaI and HindIII sites of pBS(/) (Stra-
plasmids used for each transfection experiment was 15
tagene). The CAT reporter gene was then cloned down-
mg, and the plasmid pBS(/) (Stratagene) was used to
stream of these cis elements. The resulting plasmids
make up the difference.
were named pABCDCAT, pAB2mlCDCAT, and pAB2m4C-
DCAT, respectively. pBCDCAT was constructed by in- Preparation of nuclear extract
serting the BCDCAT fragment, which included Cp and
the B fragment of ENII, into XbaI and HindIII sites of The preparation of nuclear extract was performed basi-
cally according to the method described by Andreas andpBS(/). The construction of pABCDCAT and pBCDCAT
is illustrated in Fig. 1. Faller (1991). All steps were carried out under 47. Cells
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(1 1 107) were harvested and washed three times with which are preferentially expressed in liver cells (Dikstein
et al., 1990). Therefore, this motif in the B2 sequence11 PBS. After centrifugation, the pellet was resuspended
in 400 ml buffer A (10 mM HEPES–KOH, pH 7.9; 10 mM may aslo be important for the function of ENII. Based on
this assumption, two mutated B2 fragments were de-KCl; 1.5 mM MgCl2 ; 1 mM DTT; 1 mM PMSF), kept on
wet ice for 15 min, and then homogenized in a dounce signed. B2ml contains only a single-nucleotide mutation
which changed TGTTTGTTT to TCTTTGTTT, while thehomogenizer with B pestle about 20–25 strokes. Centri-
fuged at maximum speed, the nuclear pellet was resus- other, B2m4, changed four nucleotides within this motif
(TGTTTGTTT to TGGATCCTT).pended in 200 ml buffer B (20 mM HEPES–KOH, pH 7.9;
420 mM NaCl; 0.2 mM EDTA; 25% glycerol; 1.5 mM pABCDCAT (Fig. 1), pAB2mlCDCAT, and pAB2m4CD-
CAT were constructed as described under Materials andMgCl2 ; 1 mM DTT; 1 mM PMSF). The mixture was kept
on wet ice for 20 min. After centrifugation at 15000 rpm Methods. These constructs were transfected into HepG2
cells, respectively, and CAT expression was measured.for 2 min, the supernatant was collected and frozen im-
mediately in liquid nitrogen in small aliquots. Nuclear The result was striking. pABCDCAT, which contained the
wild-type ENII and Cp, drove very strong CAT expressionextracts were stored at 0707. The concentration of the
protein was determined using Bradford method ac- as expected. But the levels of expression of the other
two constructions were extremly low compared with thatcording to the description provided by the manufacturer
(Bio-Rad). of pABCDCAT (Fig. 2a), suggesting that the TGTTTGTTT
motif may be critical for the function of ENII. Impressively,
one single mutation (G to C) within the TGTTTGTTT motifElectrophoresis mobility shift assay (EMSA)
was sufficient to cause such an apparent decline of CAT
EMSA was performed essentially as described activity.
(Drewes et al., 1991). In the binding reaction, 32P-end- Since ENII partly overlapped Cp, it was worth investi-
labeled probe (0.1–1 ng, 10,000 cpm) was mixed with gating whether such a decrease in CAT expression was
2–6 mg nuclear extract and 1–2 mg poly(dI–dC) (Phar- due to the reduced activity of ENII or the interference
macia). After incubation at room temperature for 30 min, with the normal function of the core promotor. To answer
the mixture was resolved on a 5% nondenaturing poly- this question, two sets of plasmids containing ENII down-
acrylamide gel. After electrophoresis at a strength of 10 stream of the CAT gene were constructed. The first set
v/cm, the gel was dried under vacuum and autoradio- of construction used B3C, i.e., the viral basic Cp (unpub-
graphed for 12–72 hr at 0707. In the competition assay, lished data), as promoter to drive the transcription, while
competitors were incubated with nuclear extract and the other used the heterologous SV40 early promoter
poly(dI–dC) at 07 for 10 min prior to the addition of probe. (Fig. 1). CAT assay results (Figs. 2b and 2c) clearly re-
In supershift assay, 1 ml respective anti-HNF3 serum was vealed that the mutations within the TGTTTGTTT motif
mixed with nuclear extract before adding the probe. reduced the activity of ENII rather than disabled the nor-
Oligonucleotides used in EMSA were the following: mal function of Cp. These results further convinced us
ENII–B2, 5* nt 1709-CTTCAAAGACTGTTTGTTTAAG3*, 3* that the TGTTTGTTT motif was essential for the activity
GAAGTTTCTGACAAACAAATTC5*-nt 1730; HNF3 (Ri- of ENII.
gaud et al., 1991), 5* ACGCAGGACTTGTTTGTTCTAG3*,
3* TGCGTCCTGAACAAACAAGATC 5*; ENII–B2ml, 5* nt
HNF3a and HNF3b could interact with the B21704-GCATACTTCAAAGACTcTTTGTTTAAGGACTGG-3*,
fragment at the TGTTTGTTT motif specifically3* CGTATGAAGTTTCTGAgAAACAAATTCCTGACC-5*-nt
1736; ENII–B2m4, 5* nt 1704-GCATACTTCAAAGACTG- ENII is highly liver tropic, implying that the factor(s)
gaTccTTAAGGACTGG-3*, 3* CGTATGAAGTTTCTGAC- with which it interacted is liver-specific or liver-enriched.
ctAggAATTCCTGACC-5*-nt 1736. Through sequence alignment, we found that the B2 frag-
ment shared high homology with the consensus DNA
RESULTS binding sequence of HNF3 (Overdier et al., 1994). Using
the B2 fragment as labeled probe, EMSA revealed thatThe TGTTTGTTT motif is essential for the activity
there were specific shifts with HepG2 cell nuclear ex-of ENII
tracts but not with HeLa cell nuclear extracts. As shown
in Fig. 3a, two specific bands were resolved (a and b),The B2 fragment of HBV ENII contains a major trans-
acting factor binding site (Wang et al., 1990; Wu et al., which could be competed efficiently by unlabeled wild-
type B2 fragment but not two mutants, B2ml and B2m4.1992). In order to determine the function of B2 and the
property of the factor(s) interacting with it, mutational Moreover, these two bands could also be competed if
unlabeled HNF3 DNA binding consensus sequence wasanalysis was performed. Sequence analysis showed that
there is a TGT3 motif, TGTTTGTTT (nt 1719–1727), within incubated with HepG2 nuclear extract prior to the addi-
tion of the labeled B2 probe. In addition, EMSA usingthe B2 fragment. The TGT3 motif appears in the functional
promoters and enhancers of several cellular genes HNF3 consensus oligonucleotides as labeled probe
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FIG. 2. Relative CAT activity of wild-type and mutant ENII in HepG2 cells. HepG2 cells were transfected with plasmids as described under Materials
and Methods. (a) pABCDCAT and its mutant forms, pAB2mlCDCAT and pAB2m4CDCAT; (b) pSVpCATAB and its mutant forms, pSVpCATAB2ml and
pSVpCATAB2m4; (c) pB3CCATAB and its mutant forms, pB3CCATAB2ml and pB3CCATAB2m4. AB represented wild-type ENII, while AB2ml and
AB2m4 the mutated ENII. pCH110 (Pharmacia) was cotransfected as internal control for the transfection efficiency. The CAT activities of the wild-
type plasmids were taken as 100%, respectively.
showed a shift pattern (bands I and II) very similar to it also existed when the probes were incubated only with
the anti-HNF3 sera (data not shown). The reason thatthat of the B2 probe (Fig. 3b). In the competition assay,
both unlabeled HNF3 consensus oligonucleotides and the addition of anti-HNF3 sera caused elimination of the
bands instead of forming supershift may be due to thewild-type B2 fragments could compete bands I and II
specifically and efficiently, indicating that the factor bind- possibility that anti-HNF3 sera blocked the interaction of
HNF3 with DNA by binding to the factor so that HNF3ing to the B2 fragment was likely to be HNF3.
To further investigate whether HNF3 really interacted could no longer bind DNA. The above results comfirmed
that HNF3a and HNF3b were the factors interacting withwith the B2 fragment, anti-HNF3 sera were used in su-
pershift assay. As shown in Fig. 3c, incubation of anti- the B2 fragment.
HNF3a serum with HepG2 nuclear extract prior to the
addition of labeled B2 fragment resulted in the elimina- Regulation of the activity of ENII by HNF3
tion of band a, while anti-HNF3b serum caused the dis-
appearance of band b. However anti-HNF3g serum had To investigate the functional importance of HNF3 in
regulating the activity of ENII, a series of plasmids con-no effect on the binding pattern. Band N was not a spe-
cific supershift band. It represented the nonspecific inter- taining HNF3a, HNF3b, and HNF3g cDNA in the anti-
sense orientation were constructed. These constructsaction between B2 probe and anti-HNF3 serum, because
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FIG. 3. Electrophoresis mobility shift assay and supershift assay of the HBV ENII B2 fragment and HNF3 oligonucleotide. (a) EMSA of the B2
fragment. 32P-end-labeled B2 probe was incubated with HepG2 nuclear extract. Lane 1, the labeled B2 probe; nuclear extract was omitted. Lane 2,
B2 probe with nuclear extract. Lanes 3 and 4, unlabeled B2 was used as competitor to demonstrate the specificity of binding bands (lane 3, 12
molar excess; lane 4, 60 molar excess). Lanes 5 and 6, mutant B2 as competitor (lane 5, B2m4, 60 molar excess; lane 6, B2ml, 60 molar excess).
Lanes 7 and 8, the HNF3 DNA binding consensus oligonucleotide was used as competitor (lane 7, 12 molar excess; lane 8, 60 molar excess).
Lane 9, nonspecific competitor (pBS/HaeIII-digested mixture, 60 molar excess). (b) EMSA of the HNF3 DNA binding consensus oligonucleotide.
Lane 1, 32P-end-labeled B2 probe with HepG2 cell nuclear extract. Lane 2, 32P-end-labeled HNF3 oligonucleotide probe with HepG2 cell nuclear
extract. Lane 3, unlabeled HNF3 oligonucleotide as competitor (60 molar excess). Lane 4, unlabeled B2 of HBV ENII as competitor (60 molar excess).
Lane 5, nonspecific competitor (pBS/HaeIII-digested mixture, 60 molar excess). (c) Supershift assay of the B2 fragment. Anti-HNF3 serum was
added to demonstrate which member of the HNF3 family bound to B2 probe. Lane 1, B2 probe with HepG2 nuclear extract; antiserum was omitted.
Lane 2, anti-HNF3a serum. Lane 3, anti-HNF3b serum. Lane 4, anti-HNF3g serum.
(pAntiHNF3a, pAntiHNF3b, pAntiHNF3g) and pCMV/ ment of ENII. Antisense HNF3g showed no influence,
which was in accordance with an in vitro binding assay.poly, the control expression vector, were cotransfected
with pABCDCAT or pBCDCAT into HepG2 cells, respec- More convincing data came from the cotransfec-
tion assay, in which pCMVHNF3a, pCMVHNF3b,tively. CAT analysis indicated that antisense HNF3a and
HNF3b could suppress the function of ENII in HepG2 pCMVHNF3g, and pCMV/poly were cotransfected into
HeLa cells with pBCDCAT, respectively. Normally, therecells (Figs. 4a and 4b), while pCMV/poly showed no influ-
ence (data not shown). The decrease of the activity of was very poor CAT expression when only pBCDCAT was
transfected into HeLa cells, which was clear proof of theENII was dose dependent. The effects on pBCDCAT were
more obvious than that on pABCDCAT (Figs. 4a and 4b), liver specificity of ENII. The control plasmid pCMV/poly
showed no effect on the activity of pBCDCAT. However,suggesting that HNF3 interacted mainly with the B frag-
/ m4655$7625 11-13-95 21:06:25 vira AP-Virology
376 LI ET AL.
FIG. 4. Relative CAT activity of pABCDCAT and pBCDCAT in HepG2 cells cotransfected with antisense HNF3 plasmids. (a) Different amounts of
antisense HNF3 plasmid (pAntiHNF3a, pAnitHNF3b, or pAntiHNF3g) as described under Materials and Methods were cotransfected with 1.5 mg
pABCDCAT into HepG2 cells. (b) Different amounts of antisense HNF3 plasmid were cotransfected with 1.5 mg pBCDCAT into HepG2 cells. pCMV/
SEAP (1.0 mg) was included as internal control for transfection efficiency. The CAT activities of pABCDCAT and pBCDCAT were taken as 100%,
respectively.
the ENII activity increased remarkably when cotrans- the activity of pAB2m4CDCAT could not be stimulated by
HNF3b (data not shown). This supported the fact thatfected with pCMVHNF3b (Fig. 5), indicating that HNF3b
could switch on the function of ENII in HeLa cells. It HNF3b activated ENII function through the B2 fragment
of ENII.should be pointed out that HNF3a and HNF3g did not
influence the activity of ENII in the same manner as The above data showed clearly that HNF3 and espe-
cially HNF3b played an important role in the functionHNF3b did in our experiments (Fig. 5).
Similar results were obtained when pABCDCAT was and liver specificity of HBV ENII. It interacted with the
B2 fragment of ENII directly and regulated the activity ofcotransfected with pCMVHNF3b in HeLa cells. However,
if mutations were introduced into the B2 fragment of ENII, ENII. Since HNF3 is liver-enriched, it is likely that HNF3
may at least partly contribute to the liver specificity
of ENII.
DISCUSSION
The B fragment is the basic functional unit of HBV ENII
(Wu et al., 1992). Within this fragment, there is one major
trans-acting factor binding site (nt 1714–1730). Given the
critical role that ENII played in the regulation of liver-
specific viral gene transcription, it is important to under-
stand the function of this binding site as well as the
property of the corresponding bound factor(s). In this
paper, using PCR-mediated site-directed mutagenesis,
we found that mutations of individual nucleotides in the
TGTTTGTTT motif within this binding site could cause a
significant decrease in the activity of ENII. Chen et al.
(1993) reported that mutations in nt 1713–1720 and nt
1708–1720 (mutations M-5 and M-4/5) caused a de-
crease in enhancer activity, which was in good accor-
FIG. 5. Relative CAT activity of pBCDCAT in HeLa cells cotransfected dance with our data. However, mutations within nt 1720–
with HNF3 expression plasmids. pBCDCAT (1.5 mg) was cotransfected 1727 (mutation M-6) resulted no significant loss of func-
with different amounts of HNF3 eukaryotic expression plasmids
tion of ENII in their study. The reason for this disaccor-(pCMVHNF3a, pCMVHNF3b, pCMVHNF3g) into HeLa cells. pCMV/
dance was not clear. In our mutation analysis, it wasSEAP (1.0 mg) was included as internal control. The CAT activity was
indicated as the percentage of the acetyl form of [14C]chloramphenical. worth pointing out that one single conversion of nt 1720
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from G to C in TGTTTGTTT was sufficient to reduce the vated ENII function through the B2 fragment. Interest-
ingly, we detected the effect of HNF3 on ENII in HeLaenhancer activity greatly, indicating that the first G in
TGTTTGTTT was crucial for trans–cis recognition. We cells, which was different from theirs. The reason may
lie in the fact that the original HBV Cp, instead of othercompared all the known sequences of hepatitis B viruses
and found that this nucleotide was 100% conserved (data heterologous promoters, was used in our study. This may
prompt the fact that the cooperation between HNF3 andnot shown). Thus it further supports the possibility that
this nucleotide is an important site during trans–cis inter- other cofactors that interacted with the core promotor is
necessary to achieve the full function of ENII.action.
EMSA revealed that HNF3 could interact with the B2 Due to its high hepatocyte specificity, ENII serves as
a good model for studying cell type-specific gene tran-fragment specifically. The integrity of the TGTTTGTTT
motif was essential for such an interaction. Ori and Shaul scription. Guo et al. (1993) showed that HNF4, another
liver-enriched transcription regulatory factor, could bind(1995) also reported that HNF3 could bind to the TGTTT
site within HBV ENI, further confirming that TGTTT was to nt 1650–1674 within the genome of HBV, which was
nearly identical to the A fragment in our study. We foundthe motif important for the interaction of HNF3 with HBV
enhancers. that HNF1, a major hepatocyte transcription factor, could
bind directly to the B fragment within ENII (unpublishedHNF3 is a family of liver-enriched transcription factors.
The binding sites of HNF3 on cis elements have been results). Besides, C/EBP, a common liver-enriched factor,
was also observed to regulate the function of ENII (Lo-identified in the regulatory sequences of several hepato-
cyte-specific genes including albumin, a-fetoprotein, a-1- pez-Cabrera et al., 1990). Together with HNF3 as shown
in this paper, it is likely that each liver-specific or liver-antitrypsin, transthyretin tyrosine aminotransferase, etc.
The interaction between HNF3 and cis DNA regulatory enriched factor contributes partly to the liver-specific ac-
tivity of ENII. The interaction of these factors remains anelements correlated with the liver-specific expression of
these genes (Lai et al., 1991; Lai and Darnell, 1991). interesting question which will greatly help us to under-
stand the regulation of cell type-specific gene transcrip-Three members of the HNF3 family (HNF3a, HNF3b,
HNF3g) have been so far identified and cloned. Their tion.
DNA binding domains are highly conserved, which can
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